Brief: Spectrum Pharmaceuticals’ROLVEDON (Eflapegrastim-Xnst) Injection Added To NCCN Supportive Care Guidelines In Oncology For Hematopoietic Growth Factors
06/12/2022 12:40
Dec 6 (Reuters) - Spectrum Pharmaceuticals Inc SPPI.O :
* SPECTRUM PHARMACEUTICALS’ ROLVEDON™ (EFLAPEGRASTIM-XNST)
INJECTION ADDED TO NCCN SUPPORTIVE CARE GUIDELINES IN ONCOLOGY
FOR HEMATOPOIETIC GROWTH FACTORS
Source text for Eikon: ID:nBw4LX0NTa
Further company coverage: SPPI.O
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary